Fulgent Genetics, Inc. gets a $640,000 investment from TD Asset Management Inc.

In its most recent Form 13F filing with the Securities and Exchange Commission, TD Asset Management INC declared that they'd increased the Fulgent Genetics, INC stock they own. This deal was made at some point in the third quarter of the fiscal year.

‍

The institutional investor paid about $640,000 for 16,500 shares of the company's stock, bringing the total amount the investor spent to about $640,000.

‍

Fulgent Genetics' most recent filing with the SEC shows that TD Asset Management INC owns a 0.05% stake in the company.

‍

In the past few months, several large investors have changed how much of the company's stock they own. In the first three months of 2018, Geneos Wealth Management INC bought 416.8% more Fulgent Genetics stock. Geneos Wealth Management INC owns 491 shares of the company's stock worth $30,000 after buying 396 more shares during the most recent fiscal quarter.

‍

During the second quarter of 2018, Total Clarity Wealth Management Inc. put about $29 thousand into Fulgent Genetics.

‍

Over the past three months, the amount of Fulgent Genetics stock that Ronald Blue Trust INC owns has grown by 1,114.0%. After buying another 557 shares in the most recent fiscal quarter, Ronald Blue Trust INC now has a total of 607 shares worth $33,000.

‍

In the second quarter of the fiscal year, Banque Cantonale Vaudoise bought an additional 86.6% of Fulgent Genetics, bringing the company's total ownership to 100%.

‍

Banque Cantonale Vaudoise now owns a total of 1,153 shares of the company's stock, which are worth $63,000. This is because the bank bought 535 more shares during the most recent fiscal quarter.

‍

Last but not least, KBC Group NV spent an extra $93,000 during the second quarter to buy more Fulgent Genetics shares. Institutional investors and hedge fund investors own about 43.22 percent of the company's stock as a group. Investors in hedge funds also own a big chunk of the company's stock.

‍

The NASDAQ FLGT market opened on Friday at $32.17.

‍

During the last year, the price of Fulgent Genetics, INC went up and down from $28.53 to $73.47. When they were at their lowest, each one cost $28.53. The moving average of the stock price over the last 200 days is $39.19, while the moving average over the last 50 days is $32.52.The company's price-to-earnings ratio is 3.70, its beta value is 1.58, and its market cap is $947.02 million at the moment.

‍

The most recent quarterly earnings report for Fulgent Genetics came out on November 7, 2017. The company's actual earnings per share (EPS) for the quarter came in at $0.11. This was $0.13 more than the average estimate at the beginning of the quarter, which was $0.02. The company said that its earnings per share (EPS) for the quarter were $0.11, which was $0.13 more than the average estimate of $0.02 per share.

‍

Fulgent Genetics' return on equity was 22.10%, and the company's net margin was 33.82%.

‍

The revenue for the quarter was $105.66 million, which was a lot more than the $103.70 million that analysts had predicted.

‍

Professionals in the industry thought that Fulgent Genetics, INC would make $4.93 per share in revenue in 2018. Several brokerage houses have put out reports on FLGT in the past few weeks. These studies focus on things that have happened more recently.

‍

In a research report released on December 8, Piper Sandler lowered their price target for Fulgent Genetics from $65.00 to $40.00 and changed the company's rating from "overweight" to "neutral." On November 18, shares of Fulgent Genetics were covered by Raymond James for the first time.

‍

At first, only people in the United States could get this coverage. They gave the stock a "outperform" rating and predicted that by the end of the year, each share would be worth $45.00.

‍

In a research report released on November 14, the "outperform" rating and price objective that Credit Suisse Group had previously placed on Fulgent Genetics decreased from $65.00 to $50.00.

‍

This change was made to the company's stock price.

‍

Two of the four analysts have assigned the stock a rating of "hold," while the other two have ratings of "buy." The information discovered on Bloomberg.com indicates that the company is currently projected to reach a price of $45.00 and has been given a rating of "Moderate Buy" as the average recommendation.

A technological company called Fulgent Genetics, INC offers services, including the sequencing and testing of genes. Customers can obtain these services.

‍

It offers solutions to known mutations, inherited cancer, carrier screening, tumor profiling, genes, and panel testing.

‍

The company was established on May 13, 2016, and it currently has its headquarters in Temple City, which is found in the state of California.

‍